Клинические и иммунологические аспекты пневмококковой вакцинации у пациентов с множественной миеломой

Актуальность. Среди групп высокого риска развития инвазивных пневмококковых инфекций пациенты с множественной миеломой (ММ) выделяются одними из самых высоких показателей первичной заболеваемости и летальности по причине наличия глубокой иммуносупрессии. Цель: обозначить современное состояние проблемы вакцинопрофилактики пневмококковой инфекции у пациентов, получающих лечение по поводу множественной миеломы, обосновать доказательную базу вакцинации коньюгированной пневомококковой вакциной. В работе применялся метод сплошного обзора данных в отношении исследований на тему вакцинации против пневмококковой инфекции у пациентов с множественной миеломой. Выводы. В статье представлены современные эпидемиологические данные, а также результаты оригинальных исследований клинических и иммунологических аспектов пневмококковой вакцинации у пациентов с ММ, получающих новые таргетные агенты и иммунопрепараты. Обозначена эффективность применения коньюгированной пневмококковой вакцины у пациентов на фоне лечения ММ бор-тезомибом, леналидомидом, иксазомибом. Показано независимое защитное влияние пневмококковой вакцинации как меры профилактического воздействия в когорте пациентов с ММ на фоне лечения новыми таргетными лекарственными средствами.

1. Kamboj, M, Shah, MK. Vaccination of the stem cell transplant recipient and the hematologic malignancy patient. Infectious Disease Clinics of North America. 2019;33(2):593-609.

2. Meroni, PL. Zavaglia, D, Girmenia, C. Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs. Clinical and Experimental Rheumatology. 2018;36(2):317-328.

3. Monier, A, Puyade M., Gallego Hernanz MP, et al. Observational study of vaccination in cancer patients: How can vaccine coverage be improved? Medecine Et Maladies Infectieuses. 2020;50(3); 263-268. D0l:10.1016/j.medmal.2019.11.006

4. Klu gman, KP, Madhi, SA, Feldman, C. HIV and pneumococcal disease. Current opinion in infectious diseases. 2007(20)1:11-15.

5. Shatz, DV. Vaccination considerations in the asplenic patient. Expert review of vaccines. - 2005;4(1):27-34.

6. Augustson, BM, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005;23(36):9219-9226.

7. Blimark, C, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(10):107-113.

8. Hallam, S. TEAMM Work Saves Lives in Myeloma. HemaSphere. 2018;2(1):E24.

9. Zarco-Marquez, S, et al. Invasive and complicated pneumococcal infection in patients with cancer. Revista De Investigation Clinica; Organo Del Hospital De Enfermedades De La Nutricion. 2016;68(5):221-228.

10. Chong, PP, Avery, RK. A comprehensive review of immunization practices in solid organ transplant and hematopoietic stem cell transplant recipients. Clinical Therapeutics. 2017; 39(8):1581-1598.

11. Langedijk, AC, et al. Long-term pneumococcal vaccine immunogenicity following allogeneic hematopoietic stem cell transplantation. Vaccine. 2019;37(3):510-515.

12. Palazzo, M, et al. Revaccination after Autologous hematopoietic stem cell transplantation is safe and effective in patients with multiple myeloma receiving lenalidomide maintenance. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2018;24(4):871-876.

13. Cordonnier, C, et al. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine. 2010;28(15):2730-2734.

14. Cordonnier, C, et al. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged >2 years: an open-label study. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2015;61(3):313-323.

15. Tsigrelis, C, Ljungman, P. Vaccinations in patients with hematological malignancies. Blood Reviews. 2016;30(2)139-147.

16. Cordonnier, C, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). The Lancet. Infectious Diseases. 2019;19(6):E200-e212.

17. Westerink, MAJ, Schroeder, HW, Nahm, MH. Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination. Aging and Disease. 2012;3(1):17.

18. Black, SB, et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. The Pediatric Infectious Disease Journal. 1991;10(2):97-104.

19. Stein, KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. The Journal of Infectious Diseases. 1992;165(1):S49-52.

20. Kayhty, H, Eskola, J. New vaccines for the prevention of pneumococcal infections. Emerging Infectious Diseases. 1996;2(4):289-298.

21. Mccool, TL et al. B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity. INFECT. IMMUN. 1999;67:8.

22. Pletz, MW, et al. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. International Journal of Antimicrobial Agents. 2008;32(3):199-206.

23. Jochems, SP, et al. The immunological mechanisms that control pneumococcal carriage. PLoS pathogens. 2017;13(12):E1006665.

24. Иммунологическое обоснование сроков вакцинопрофилактики пневмококковой инфекции у пациентов с множественной миеломой после аутологичной трансплантации гемопоэтических стволовых клеток [Электронный ресурс]. 2020. Режим доступа: https://medmag.bsmu.by/category68/article2983/. Дата доступа: 08.05.2020.

25. Stoma, I, et al. Immunological reconstitution as a basis for the early initiation of pneumococcal vaccination after autologous hematopoietic stem cell transplantation. HemaSphere. 2019;3:342-343. -. DOI: 10.1097/01.HS9.0000561392.22749.84.

26. French, N, et al. A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults. New England Journal of Medicine. 2010;362(9):812-822.

27. Crum-Cianflone, NF, Wallace, MR. Vaccination in HIV-Infected Adults. AIDS Patient Care and STDs. 2014;28(8):397-410.

28. Gong, J, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. Journal for Immunotherapy of Cancer. 2018;6(1):8.

29. Gajewski, TF, Schreiber, H, Fu, Y.-X. Innate and adaptive immune cells in the tumor microenvironment. Nature Immunology. 2013;14(10):1014-1022.

30. Altmann, DM. A Nobel Prize-worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens. Immunology. 2018;155(3):283-284.

31. Chim, CS, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32(2):252-262.

32. Ludwig, H, et al. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2018;32(7):1542-1560.

33. Gay, F, et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica. 2018;103(2):197-211.

34. Ludwig, H, Zojer, N. Supportive care in multiple myeloma. Best Practice & Research. Clinical Haematology. 2007;20(4):817-835.

35. Rajkumar, S.V. Multiple Myeloma: 2018 update on Diagnosis, Risk-stratification and Management. American journal of hematology. 2018;93(8):981-1114.

36. Fernandez-Ruiz, M, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction). Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2018;24(2):S2-S9.

37. Stoma, I., et al. Clinical efficacy of pneumococcal vaccination in multiple myeloma patients on novel agents: Results of a prospective clinical study. Vaccine. 2020;38(30):4713-4716.

38. Mustafa, SS, et al. Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls. Human Vaccines & Immunotherapeutics. 2019;15(2):452-454.

39. Renaud, L, et al. Response to pneumococcal vaccination in multiple myeloma, Cancer Medicine. 2019;8(8):3822-3830.

40. Pasiarski, M, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with monoclonal gammopathy of undetermined significance -relationship with selected immune and clinical parameters. Clinical Interventions in Aging. 2019;14:1741-1749.

41. Babel, N, et al. Monoclonal gammopathy of undetermined significance (MGUS) is associated with an increased frequency of Epstein-Barr Virus (EBV) latently infected B lymphocytes in long-term renal transplant patients. Transplantation Proceedings. 2004;36(9):2679-2682.

42. Tete, SM, et al. Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma. Frontiers in Immunology. 2014;5:257.

43. Blade, J, et al. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia. 2008;22(9):1651-1657.

44. Kyle, RA, et al. Prevalence of monoclonal gammopathy of undetermined significance. The New England Journal of Medicine. 2006;354(13):1362-1369.

45. Kristinsson, SY, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica. 2012;97(6):854-858.

46. Rajkumar, SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet. Oncology. 2014;15(12):E538-548.

47. Kyle, RA, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. The New England Journal of Medicine. 2007;356(25):2582-2590.

48. Bahuaud, M, et al. Immunogenicity and persistence of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) in patients with untreated Smoldering Multiple Myeloma (SMM): A pilot study. Heliyon. 2017;3(11):E00441.

49. Lode, H, et al. Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1 x, 2 x, or 4 x) in healthy subjects aged 70 years or older. Vaccine. 2011;29(31):4940-4946.

50. Thompson, MA, et al. Multiple myeloma baseline immunoglobulin g level and pneumococcal vaccination antibody response. Journal of Patient-Centered Research and Reviews. 2017;4(3):131-135.

51. Beers, SA, Glennie, MJ, White, AL. Influence of immunoglobulin isotype on therapeutic antibody function. Blood. 2016;127(9):1097-1101.

52. Karlsson, J, et al. Poor correlation between pneumococcal igg and igm titers and opsonophagocytic activity in vaccinated patients with multiple myeloma and waldenstrom's macroglobulinemia. Clinical and Vaccine Immunology : CVI. 2016;2(4):379-385.

53. Hinge, M, et al. Serologic response to a 23-valent pneumococcal vaccine administered prior to autologous stem cell transplantation in patients with multiple myeloma. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica. 2012;120(11):935-940.